Genetics/Genomics News

PHILADELPHIA — In this video exclusive, Deepak L. Bhatt, MD, MPH, provides his perspective on research presented at the American Heart Association Scientific Sessions.

PHILADELPHIA — A novel single-dose CRISPR base-editing infusion for patients with heterozygous familial hypercholesterolemia and advanced CAD reduced serum PCSK9 and lowered LDL by up to 55% in one patient, a speaker reported.

The Healio team is providing live coverage of the American Heart Association's Scientific Sessions in Philadelphia.

The FDA approved the enzyme replacement therapy Adzynma for the prophylactic or on-demand treatment of adults and pediatric patients with congenital thrombotic thrombocytopenic purpura, a rare blood clotting disorder.

Recently, there have been a number of cases in which high-profile athletes have had sudden cardiac arrest due to a variety of causes.

Despite advances made for the treatment and management of hypertrophic cardiomyopathy, the condition remains a debilitating one for many patients, who are often undiagnosed until the disease has progressed.

Genetic predisposition to denture use was associated with increased likelihood of cardiometabolic diseases and related risk factors including dyslipidemia and elevated waist circumference, researchers reported.

Monthly lerodalcibep on top of maximum tolerated therapy reduced LDL an additional 60% over 24 weeks in patients with heterozygous familial hypercholesterolemia, with a safety profile similar vs. placebo, a speaker reported.

The FDA has approved the use of Veopoz for treatment of adults and children aged 1 year and older with CHAPLE disease, also known as CD55-deficient protein-losing enteropathy.

Following SARS-CoV-2 infection, mitochondrial function remained impaired in the heart, liver and kidneys, despite observed recovery in the lungs, according to a human autopsy and animal tissue study.